Mapi Pharma Publishes Revised $20M Prospectus For IPO

July 28, 2014 | Mapi Pharma, which was scheduled to complete a $37 million financing round by the end of last week, has published a revised prospectus for $20 million. As a result the company value for the IPO was lowered to $120 million after money. Aegis Capital is leading the IPO along with Chardan Capital as the second underwriter. Mapi Pharma is headed by CEO Ehud Marom and manufactures complicated-to-procedure raw materials for generic drugs and has a technological platform for delayed drug release.